The mutational status of PTEN is important in the development of various cancers, including liver, breast, lung, and prostate cancers [1], where its loss or inactivation is associated with increased activity of the PI3K/AKT pathway, leading to increased cell proliferation and the inhibition of programmed cell death (apoptosis) [2]. Here, PTEN is linked to prostate carcinoma.